Table S2 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Q: What type of study is this?

This is a Experimental Study study.

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304666

October 8, 2025

Table S2 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

The combination of RAS pathway inhibitors with targeted agents shows potential effectiveness in treating cancer.
Patient-derived spheroids exhibit distinct responses to treatments based on their kras status and tumor types.
This analysis includes various malignant cell lines, emphasizing diverse cancer types and their specific challenges.
The findings could lead to innovative therapeutic approaches tailored to individual kras variant profiles.

Implication

Analysis showcases the effectiveness of targeted agents in oncogenic kras variants within patient-derived tumor spheroids, implying potential therapeutic strategies.

Abstract

Table S2. The malignant cell lines grown as multicell-type tumor spheroids for this study. The names of both patient-derived and established cell lines are listed along with the tumor type they were derived from and the KRAS status.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3bb0 https://doi.org/10.1158/2767-9764.30304666

View Full Paper

Ask AI

Bookmark

Share

Table S2 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Table S2 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading